- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Nexgel Inc (NXGL)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: NXGL (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.51% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.55M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 1.45 - 4.00 | Updated Date 01/9/2026 |
52 Weeks Range 1.45 - 4.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -24.69% | Operating Margin (TTM) -24.71% |
Management Effectiveness
Return on Assets (TTM) -16.78% | Return on Equity (TTM) -52.83% |
Valuation
Trailing PE - | Forward PE 15.2 | Enterprise Value 16097326 | Price to Sales(TTM) 1.19 |
Enterprise Value 16097326 | Price to Sales(TTM) 1.19 | ||
Enterprise Value to Revenue 1.38 | Enterprise Value to EBITDA -0.85 | Shares Outstanding 8142766 | Shares Floating 6913601 |
Shares Outstanding 8142766 | Shares Floating 6913601 | ||
Percent Insiders 15.39 | Percent Institutions 6.43 |
Upturn AI SWOT
Nexgel Inc

Company Overview
History and Background
Nexgel Inc. is a company focused on the development and commercialization of innovative healthcare products. While specific founding details and early milestones are not widely publicized, the company has been active in pursuing advancements in medical devices and related technologies. Its evolution appears to be driven by a focus on addressing unmet needs in various healthcare segments through technological innovation.
Core Business Areas
- Medical Device Development and Commercialization: Nexgel Inc. is primarily engaged in the research, development, and commercialization of innovative medical devices. This encompasses a range of products aimed at improving patient outcomes and addressing specific medical challenges.
- Biotechnology and Pharmaceutical Applications: The company also explores opportunities in biotechnology and pharmaceutical applications, potentially involving the development of novel drug delivery systems or therapeutic solutions.
Leadership and Structure
Information regarding Nexgel Inc.'s specific leadership team and detailed organizational structure is not readily available in public domain. As a publicly traded company, it is expected to have a board of directors and executive management responsible for its strategic direction and operations.
Top Products and Market Share
Key Offerings
- Description: Nexgel Inc. is known for developing advanced materials and technologies, particularly in the realm of hydrogels, which have applications in various medical fields. These may include wound care, drug delivery, and medical implants. Specific market share data for individual products is not publicly available.
- Product Name: Nexgel's proprietary technologies (specific product names not widely disclosed)
Market Dynamics
Industry Overview
Nexgel Inc. operates within the broader medical device and healthcare technology sectors. This industry is characterized by rapid innovation, significant R&D investment, stringent regulatory requirements, and a growing demand driven by an aging global population and increasing prevalence of chronic diseases. Competition is intense, with both established players and emerging startups vying for market share.
Positioning
Nexgel Inc. appears to position itself as an innovator in advanced material science, particularly hydrogel technology, aiming to create novel solutions for unmet medical needs. Its competitive advantage may lie in its proprietary technology and its ability to develop specialized applications in niche healthcare markets.
Total Addressable Market (TAM)
The Total Addressable Market for Nexgel Inc.'s potential product applications, such as advanced wound care, drug delivery systems, and medical implants, is substantial and continues to grow. Precise figures for Nexgel's specific TAM are not readily available, but the overall market for these segments runs into billions of dollars globally. Nexgel Inc. is positioned to target specific niches within this broad TAM, leveraging its technological expertise.
Upturn SWOT Analysis
Strengths
- Proprietary hydrogel technology
- Focus on innovation and unmet medical needs
- Potential for diverse applications across healthcare segments
Weaknesses
- Limited public information on product pipeline and commercialization progress
- Potentially smaller market presence compared to established competitors
- Dependence on R&D success and regulatory approvals
Opportunities
- Growing demand for advanced wound care solutions
- Expansion into novel drug delivery systems
- Partnerships with larger healthcare companies for market access
- Increasing adoption of minimally invasive medical devices
Threats
- Intense competition from established medical device companies
- Stringent and evolving regulatory landscape
- Challenges in product adoption and market penetration
- Potential for technological obsolescence
Competitors and Market Share
Key Competitors
- CorMatrix (now part of Synapse Biomedical Inc.)
- Celanese Corporation (through its medical-grade polymers)
- DSM (healthcare materials)
Competitive Landscape
Nexgel Inc. faces competition from companies specializing in advanced materials, medical devices, and drug delivery systems. Its ability to compete will depend on the uniqueness and efficacy of its patented technologies, its speed to market, and its ability to secure strategic partnerships for wider distribution and adoption.
Growth Trajectory and Initiatives
Historical Growth: Information on Nexgel Inc.'s historical growth trends is limited due to the scarcity of publicly reported financial data. The company's growth trajectory is likely tied to the success of its R&D efforts and the commercialization of its innovative technologies.
Future Projections: Specific future growth projections based on analyst estimates for Nexgel Inc. are not readily available in public financial reports. The company's future growth will depend on its ability to successfully bring its developed products to market and gain traction in its target segments.
Recent Initiatives: Recent strategic initiatives for Nexgel Inc. are not extensively publicized. The company's focus is likely on continued product development, seeking partnerships, and navigating the regulatory pathway for its innovations.
Summary
Nexgel Inc. operates in the innovative healthcare sector with a focus on advanced materials like hydrogels. The company's strengths lie in its proprietary technology and potential for diverse medical applications. However, a lack of readily available public financial and operational data makes a comprehensive assessment challenging. Key areas to watch are its ability to secure funding, navigate regulatory hurdles, and successfully commercialize its innovations in a competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge
- Publicly available company information (limited)
Disclaimers:
This JSON output is based on publicly available information and general industry knowledge. Specific financial data and detailed operational information for Nexgel Inc. are not consistently available in the public domain. Investors should conduct their own thorough due diligence and consult with financial professionals before making any investment decisions. Market share data for Nexgel Inc. and its competitors is not precisely quantifiable without specific reporting. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexgel Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2021-12-22 | CEO, President & Director Mr. Adam R. Levy | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 19 | Website https://nexgel.com |
Full time employees 19 | Website https://nexgel.com | ||
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

